严重急性呼吸综合征冠状病毒2变种与疫苗接种。
SARS-CoV-2 variants and vaccination.
作者信息
Liu Yang, Liu Jianying, Shi Pei-Yong
机构信息
Institute of Infectious Disease, Shenzhen Bay Laboratory, Shenzhen, Guangdong, China.
Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
出版信息
Zoonoses. 2022;2(1). doi: 10.15212/zoonoses-2022-0001. Epub 2022 Feb 8.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused global destruction since its emergence in late 2019. Over the past two years, the virus has continuously evolved in human host, leading to emergence of variants with changed viral transmission, disease severity, and evasion of immunity. Although vaccines have been developed for the coronavirus disease 2019 (COVID-19) at an unprecedently pace, the variants have constantly posed threats to the effectiveness of the approved vaccines. In this short communication, we review the key variants and discuss their implications in viral replication, transmission, and immune evasion.
摘要
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）自2019年末出现以来已造成全球破坏。在过去两年中，该病毒在人类宿主中不断进化，导致出现了病毒传播、疾病严重程度和免疫逃逸发生变化的变种。尽管针对2019冠状病毒病（COVID-19）的疫苗以前所未有的速度研发出来，但这些变种不断对已获批疫苗的有效性构成威胁。在这篇简短的通讯中，我们综述了关键变种，并讨论它们在病毒复制、传播和免疫逃逸方面的影响。
相似文献
1
SARS-CoV-2 variants and vaccination.
Zoonoses. 2022;2(1). doi: 10.15212/zoonoses-2022-0001. Epub 2022 Feb 8.
2
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
3
Research progress in spike mutations of SARS-CoV-2 variants and vaccine development.
Med Res Rev. 2023 Jul;43(4):932-971. doi: 10.1002/med.21941. Epub 2023 Mar 16.
4
Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains.
Viruses. 2022 Apr 16;14(4):827. doi: 10.3390/v14040827.
5
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
Front Cell Infect Microbiol. 2021 Sep 10;11:690621. doi: 10.3389/fcimb.2021.690621. eCollection 2021.
6
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
7
Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
Infect Genet Evol. 2022 Jan;97:105164. doi: 10.1016/j.meegid.2021.105164. Epub 2021 Nov 27.
8
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
9
SARS-CoV-2 Variants, Vaccines, and Host Immunity.
Front Immunol. 2022 Jan 3;12:809244. doi: 10.3389/fimmu.2021.809244. eCollection 2021.
10
COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.
Bull Natl Res Cent. 2022;46(1):96. doi: 10.1186/s42269-022-00787-z. Epub 2022 Apr 8.
引用本文的文献
1
Single cell transcriptomics correlate avian coronavirus prime vaccination efficacy with antigen-presenting cell preference.
NPJ Vaccines. 2025 May 18;10(1):99. doi: 10.1038/s41541-025-01154-5.
2
COVID-19 outbreaks caused by different SARS-CoV-2 variants: a descriptive, comparative study from China.
Front Public Health. 2024 Dec 12;12:1416900. doi: 10.3389/fpubh.2024.1416900. eCollection 2024.
3
Current Updates on Variants of SARS-CoV- 2: Systematic Review.
Health Sci Rep. 2024 Nov 4;7(11):e70166. doi: 10.1002/hsr2.70166. eCollection 2024 Nov.
4
Satisfaction of lecturers and undergraduate students of medical faculties in Indonesia towards online anatomy learning during COVID-19 pandemic.
BMC Med Educ. 2024 Jun 26;24(1):695. doi: 10.1186/s12909-024-05620-x.
5
Molnupiravir Inhibits Porcine Epidemic Diarrhea Virus Infection In Vitro.
Viruses. 2023 Jun 2;15(6):1317. doi: 10.3390/v15061317.
6
Advances in the application of molecular diagnostic techniques for the detection of infectious disease pathogens (Review).
Mol Med Rep. 2023 May;27(5). doi: 10.3892/mmr.2023.12991. Epub 2023 Apr 7.
7
A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
J Virol. 2023 Feb 28;97(2):e0168422. doi: 10.1128/jvi.01684-22. Epub 2023 Jan 18.
8
Validation and Establishment of the SARS-CoV-2 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction Neutralization Test.
Microbiol Spectr. 2023 Feb 14;11(1):e0378922. doi: 10.1128/spectrum.03789-22. Epub 2023 Jan 5.
9
Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages.
Emerg Microbes Infect. 2023 Dec;12(1):e2161422. doi: 10.1080/22221751.2022.2161422.
10
Approximations to Diagnosis and Therapy of COVID-19 in Nervous Systems Using Extracellular Vesicles.
Pathogens. 2022 Dec 8;11(12):1501. doi: 10.3390/pathogens11121501.
本文引用的文献
1
Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant.
Cell Rep. 2022 May 17;39(7):110829. doi: 10.1016/j.celrep.2022.110829. Epub 2022 Apr 29.
2
Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2.
Cell Host Microbe. 2022 Apr 13;30(4):485-488.e3. doi: 10.1016/j.chom.2022.02.015. Epub 2022 Feb 18.
3
Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection.
Nat Commun. 2022 Feb 9;13(1):852. doi: 10.1038/s41467-022-28544-w.
4
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
Nature. 2022 Feb;602(7898):664-670. doi: 10.1038/s41586-021-04386-2. Epub 2021 Dec 23.
5
Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
J Med Virol. 2022 Apr;94(4):1738-1744. doi: 10.1002/jmv.27524. Epub 2022 Jan 11.
6
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.
Lancet. 2021 Dec 11;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6. Epub 2021 Dec 3.
7
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
Nature. 2022 Feb;602(7896):300-306. doi: 10.1038/s41586-021-04266-9. Epub 2021 Nov 25.
8
The N501Y spike substitution enhances SARS-CoV-2 infection and transmission.
Nature. 2022 Feb;602(7896):294-299. doi: 10.1038/s41586-021-04245-0. Epub 2021 Nov 24.
9
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.
Science. 2022 Jan 21;375(6578):331-336. doi: 10.1126/science.abm0620. Epub 2021 Nov 4.
10
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343. doi: 10.15585/mmwr.mm7038e1.
Zotero 插件